News

BMO Maintains Outperform Rating on Eli Lilly (LLY), Sets $900 PT
BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...
PharmExec22h
Roundup: Pharma Giants Expand Strategic Pipelines Through Targeted M&A and Partnerships
Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...